Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$22.90|
|52 Week High||US$20.50|
|52 Week Low||US$78.22|
|1 Month Change||-16.39%|
|3 Month Change||-28.51%|
|1 Year Change||-28.62%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||27.36%|
Recent News & Updates
We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|AMTI||US Biotechs||US Market|
Return vs Industry: AMTI underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: AMTI underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: AMTI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AMTI's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company’s lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects.
Applied Molecular Transport Fundamentals Summary
|AMTI fundamental statistics|
Is AMTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMTI income statement (TTM)|
|Cost of Revenue||US$29.35m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.08|
|Net Profit Margin||0.00%|
How did AMTI perform over the long term?See historical performance and comparison
Is Applied Molecular Transport undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AMTI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AMTI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AMTI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AMTI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMTI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMTI is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (2.9x).
How is Applied Molecular Transport forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMTI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AMTI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AMTI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if AMTI's revenue is forecast to grow faster than the US market.
High Growth Revenue: AMTI is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMTI's Return on Equity is forecast to be high in 3 years time
How has Applied Molecular Transport performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AMTI is currently unprofitable.
Growing Profit Margin: AMTI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AMTI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AMTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: AMTI has a negative Return on Equity (-38.43%), as it is currently unprofitable.
How is Applied Molecular Transport's financial position?
Financial Position Analysis
Short Term Liabilities: AMTI's short term assets ($205.9M) exceed its short term liabilities ($8.1M).
Long Term Liabilities: AMTI's short term assets ($205.9M) exceed its long term liabilities ($8.0M).
Debt to Equity History and Analysis
Debt Level: AMTI is debt free.
Reducing Debt: AMTI has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMTI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AMTI has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 42.9% each year.
What is Applied Molecular Transport current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMTI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tahir Mahmood (46 yo)
Dr. Tahir Mahmood, Ph D., co-founded Applied Molecular Transport Limited Liability Company in September 2010 and serves as its Chief Business Officer. He is Co-Founder, Chief Executive Officer, and Directo...
CEO Compensation Analysis
Compensation vs Market: Tahir's total compensation ($USD621.01K) is below average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Tahir's compensation has increased whilst the company is unprofitable.
Experienced Management: AMTI's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: AMTI's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.
Applied Molecular Transport Inc.'s employee growth, exchange listings and data sources
- Name: Applied Molecular Transport Inc.
- Ticker: AMTI
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$879.925m
- Shares outstanding: 38.42m
- Website: https://www.appliedmt.com
Number of Employees
- Applied Molecular Transport Inc.
- 1 Tower Place
- Suite 850
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 23:24|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.